March 9, 2007
Corneal inlays: Another entrant into the presbyopia treatment wars
Analysis of:
Corneal inlay is versatile approach for presbyopia |
This analysis is solely the work of the author. It has not been edited or endorsed by GLG.
Implications: The early results of a new corneal inlay (PresbyLens, ReVision Optics) are presented. A corneal inlay is placed underneath a LASIK corneal flap in the non-dominant eye to correct presbyopia. This version of a corneal inlay is 1.5mm in diameter. The outcomes of 15 patients showed good uncorrected distance and near vision with 86% with 20/40 or better uncorrected near vision and 64% with 20/40 or better uncorrected distance vision.
Analysis: This version of a corneal inlay joins several other corneal inlays currently in clinical trials. Inlays from AcuFocus and Biovision incorporate a pinhole to improve near vision by increasing depth of field. On first glance the early clinical results of the Presbylens corneal inlay do not seem impressive compared to those of AcuFocus. The AcuFocus corneal inlay began clinical trials in February, 2006. The Acufocus results on a cohort of 34 patients from Istanbul presented before the clinical trials began showed most patients achieving 20/20 vision and J1 reading vision. Of note, Bausch and Lomb has made a major investment in Acufocus and is betting that this inlay will become the treatment of choice.
With a potential market of 141 million, the entry of another corneal inlay into the presbyopia treatment area speaks to the fact that this area is very hot. When compared to other presbyobia treatments, corneal inlays have several advantages including reversibility, limited decrease in distance vision, and ease of implantation. While the Presbylens may not be a winner in this area, corneal inlays are a treatment option certainly worth watching.
Analysis: This version of a corneal inlay joins several other corneal inlays currently in clinical trials. Inlays from AcuFocus and Biovision incorporate a pinhole to improve near vision by increasing depth of field. On first glance the early clinical results of the Presbylens corneal inlay do not seem impressive compared to those of AcuFocus. The AcuFocus corneal inlay began clinical trials in February, 2006. The Acufocus results on a cohort of 34 patients from Istanbul presented before the clinical trials began showed most patients achieving 20/20 vision and J1 reading vision. Of note, Bausch and Lomb has made a major investment in Acufocus and is betting that this inlay will become the treatment of choice.
With a potential market of 141 million, the entry of another corneal inlay into the presbyopia treatment area speaks to the fact that this area is very hot. When compared to other presbyobia treatments, corneal inlays have several advantages including reversibility, limited decrease in distance vision, and ease of implantation. While the Presbylens may not be a winner in this area, corneal inlays are a treatment option certainly worth watching.
Report a Concern
More GLG News in
Healthcare
Most Popular:
Source Article | Expert Analyses
Use of Antipsychotics in Children Is Criticized
www.nytimes.com
Scientists recommend 'black box' for Avastin
www.fiercepharma.com
Are Costly Diabetes Pills Doing Any Good?
www.pharmalot.com
How a Drug Maker Tries to Outwit Generics
online.wsj.com
Use of Antipsychotics in Children Poses Risks of Adverse Effects
November 26, 2008
Avastin and clots? News to me. Black box warning? Why?
November 24, 2008
Off Label Use Can Be Prevented
November 24, 2008
Gardasil will most certainly be approved for boys
November 24, 2008
Medivations's (MDVN) Dimebon - We've Seen This Movie Before
November 24, 2008

